SNTI
Senti Biosciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.67
P/S
1089.99
EV/EBITDA
-0.63
DCF Value
$-0.07
FCF Yield
-182.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-14777.3%
Operating Margin
-289668.2%
Net Margin
-279263.6%
ROE
-322.4%
ROA
-119.9%
ROIC
-149.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $22.0K | $-14.5M | $-0.53 |
| FY 2025 | $22.0K | $-61.4M | $-2.73 |
| Q3 2025 | $0.00 | $-18.1M | $-0.69 |
| Q2 2025 | $0.00 | $-14.7M | $-0.56 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
2.12
Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.